UWA-101 hydrochloride

Cat. No.:	HY-117512
CAS No.:	1431520-52-3
Molecular Formula:	$C_{13}H_{18}ClNO_2$
Molecular Weight:	255.74
Target:	Dopamine Transporter; Serotonin Transporter
Pathway:	Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

UWA-101 hydrochloride is a selective and non-cytotoxic DAT/SERT inhibitor, with EC_{50} values of 3.6 μM and 2.3 μM for inhibiting DAT and SERT, respectively. UWA-101 hydrochloride can alleviate the side effects of dopaminergic agents (such as L-DOPA), such as motor disorders, and lacks psychotropic activity. UWA-101 hydrochloride can be used for research on neurodegenerative diseases such as Parkinson's disease[1][2].

In Vivo

UWA-101 hydrochloride (3 mg/kg; i.p.; single) reduces L-DOPA-induced dyskinesia in Parkinson's disease rat model[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (250-300 g; Parkinson's disease model)[1].
Dosage:	3 mg/kg
Administration:	Intraperitoneal injection
Result:	Reduced L-DOPA-induced vertical activity by 60%.

REFERENCES

[1]. Johnston TH, et al. A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates. FASEB J. 2012 May;26(5):2154-63.

[2]. Huot P, et al. Monoamine reuptake inhibitors in Parkinson's disease. Parkinsons Dis. 2015;2015:609428.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA